MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1164/rccm.201505-0861oc

Медицинская библиотека · American journal of respiratory and critical care medicine · 2016

Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia.

Yeh Tsu F, Chen Chung M, Wu Shou Y, Husan Zahid, Li Tsai C, Hsieh Wu S, Tsai Chang H, Lin Hung C

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

RATIONALE: Bronchopulmonary dysplasia (BPD) is an important complication of mechanical ventilation in preterm infants, and no definite therapy can eliminate this complication. Pulmonary inflammation plays a crucial role in its pathogenesis, and glucocorticoid is one potential therapy to prevent BPD.

OBJECTIVES

To compare the effect of intratracheal administration of surfactant/budesonide with that of surfactant alone on the incidence of death or BPD.

METHODS

A clinical trial was conducted in three tertiary neonatal centers in the United States and Taiwan, in which 265 very-low-birth-weight infants with severe respiratory distress syndrome who required mechanical ventilation and inspired oxygen (fraction of inspired oxygen, ≥50%) within 4 hours of birth were randomly assigned to one of two groups (131 intervention and 134 control). The intervention infants received surfactant (100 mg/kg) and budesonide (0.25 mg/kg), and the control infants received surfactant only (100 mg/kg), until each infant required inspired O2 at less than 30% or was extubated.

MEASUREMENTS AND MAIN

RESULTS

The intervention group had a significantly lower incidence of BPD or death (55 of 131 [42.0%] vs. 89 of 134 [66%]; risk ratio, 0.58; 95% confidence interval, 0.44-0.77; P < 0.001; number needed to treat, 4.1; 95% confidence interval, 2.8-7.8). The intervention group required significantly fewer doses of surfactant than did the control group. The intervention group had significantly lower interleukin levels (IL-1, IL-6, IL-8) in tracheal aspirates at 12 hours and lower IL-8 at 3-5 and 7-8 days.

CONCLUSIONS

In very-low-birth-weight infants with severe respiratory distress syndrome, intratracheal administration of surfactant/budesonide compared with surfactant alone significantly decreased the incidence of BPD or death without immediate adverse effect. Clinical trial registered with www.clinicaltrials.gov (NCT-00883532).

Для цитирования: Yeh Tsu F, Chen Chung M, Wu Shou Y, Husan Zahid, Li Tsai C, Hsieh Wu S, Tsai Chang H, Lin Hung C. Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia.. American journal of respiratory and critical care medicine. 2016. DOI: 10.1164/rccm.201505-0861oc.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.